Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Intrexon Corp (XON) A Good Stock To Buy?

Page 1 of 2

Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of over 700 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has potential to beat the market over the long-term. Therefore, let’s take a closer look at what smart money thinks about Intrexon Corp (NYSE:XON).

Is Intrexon Corp (NYSE:XON) a buy right now? Hedge funds are taking a pessimistic view. The number of bullish hedge fund positions retreated by 4 lately. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as NuStar Energy L.P. (NYSE:NS), Thoratec Corporation (NASDAQ:THOR), and Allied World Assurance Co Holdings, AG. (NYSE:AWH) to gather more data points.

Follow Intrexon Corp (NYSE:XON)
Trade (NYSE:XON) Now!

According to most market participants, hedge funds are perceived as slow, old financial vehicles of years past. While there are greater than an 8000 funds trading today, Our experts look at the moguls of this group, around 700 funds. These investment experts administer bulk of all hedge funds’ total capital, and by keeping track of their unrivaled picks, Insider Monkey has discovered a few investment strategies that have historically exceeded Mr. Market. Insider Monkey’s small-cap hedge fund strategy defeated the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Keeping this in mind, we’re going to take a gander at the recent action encompassing Intrexon Corp (NYSE:XON).

What have hedge funds been doing with Intrexon Corp (NYSE:XON)?

At the end of the third quarter, a total of 17 of the hedge funds tracked by Insider Monkey held long positions in this stock, down by 19% from the second quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were increasing their stakes considerably (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Iridian Asset Management, managed by David Cohen and Harold Levy, holds the most valuable position in Intrexon Corp (NYSE:XON). The fund has reported a $60.2 million position in the stock at the end of September, comprising 0.5% of its 13F portfolio. The second largest stake is held by Dan Loeb of Third Point, with a $47.7 million position; the fund has 0.4% of its 13F portfolio invested in the stock. Some other members of the smart money with similar optimism consist of Ken Griffin’s Citadel Investment Group, James Dinan’s York Capital Management and John Thiessen’s Vertex One Asset Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!